NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma

Oncotarget

Volumn 5, Issue 23, 2014, Pages 11986-11997

  Yang, Ye ^a   Zhou, Wen ^a   Xia, Jiliang ^a   Gu, Zhimin ^a   Wendlandt, Erik ^a   Zhan, Xin ^b   Janz, Siegfried ^a   Tricot, Guido ^a   Zhan, Fenghuang ^a  

^a UNIVERSITY OF IOWA   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Aldehyde dehydrogenase; NIMA related kinase; Plasma cell myeloma; Tumor initiating cell

Indexed keywords

ALITRETINOIN; BORTEZOMIB; DOXORUBICIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; NIMA RELATED KINASE 2; PROTEIN ALDH1A1; PROTEIN BCL 2; PROTEIN KINASE B; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOID X RECEPTOR ALPHA; TUMOR MARKER; UNCLASSIFIED DRUG; ALDEHYDE DEHYDROGENASE; ALDH1A1 PROTEIN, HUMAN; NEK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RECURRENCE; CANCER RESISTANCE; CARCINOGENESIS; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; IN VIVO STUDY; MARKER GENE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NEK2 GENE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR PROMOTION; UPREGULATION; ANIMAL; APOPTOSIS; BIOSYNTHESIS; DNA MICROARRAY; DRUG RESISTANCE; FLOW CYTOMETRY; HUMAN; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ALDEHYDE DEHYDROGENASE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED NOD; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 84920054095     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2388     Document Type: Article

References (44)

1. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annual review of pathology. 2011; 6:249-274.
2. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood. 1985; 66:380-390.
3. Mohamed AN, Bentley G, Bonnett ML, Zonder J, Al-Katib A. Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes. American journal of hematology. 2007; 82:1080-1087.
4. Nilsson T, Hoglund M, Lenhoff S, Rylander L, Turesson I, Westin J, Mitelman F, Johansson B. A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age-and sex-related differences. British journal of haematology. 2003; 120:960-969.
5. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer genetics and cytogenetics. 1995; 82:41-49.
6. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446:153-158.
7. Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013.
8. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ. Characterization of clonogenic multiple myeloma cells. Blood. 2004; 103:2332-2336.
9. Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, Tiedemann RE. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer cell. 2013; 24:289-304.
10. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, Watkins DN, Huff CA, Jones RJ. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer research. 2008; 68:190-197.
11. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians. 2012; 62:10-29.
12. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nature reviews Cancer. 2013; 13:714-726.
13. Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z. NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers. Cancer cell. 2013; 23:48-62.
14. Zhou W, Yang Y, Gu Z, Wang H, Xia J, Wu X, Zhan X, Levasseur D, Zhou Y, Janz S, Tricot G, Shi J, Zhan F. ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma. Leukemia. 2013.
15. Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IP, Howell M, Kschischo M, Swanton C. Chromosomal instability confers intrinsic multidrug resistance. Cancer research. 2011; 71:1858-1870.
16. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nature genetics. 2006; 38:1043-1048.
17. Koppaka V, Thompson DC, Chen Y, Ellermann M, Nicolaou KC, Juvonen RO, Petersen D, Deitrich RA, Hurley TD, Vasiliou V. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacological reviews. 2012; 64:520-539.
18. Druesne-Pecollo N, Tehard B, Mallet Y, Gerber M, Norat T, Hercberg S, Latino-Martel P. Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer. The lancet oncology. 2009; 10:173-180.
19. Yu HS, Oyama T, Isse T, Kitakawa K, Ogawa M, Pham TT, Kawamoto T. Characteristics of aldehyde dehydrogenase 2 (Aldh2) knockout mice. Toxicology mechanisms and methods. 2009; 19:535-540.
20. Langevin F, Crossan GP, Rosado IV, Arends MJ, Patel KJ. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature. 2011; 475:53-58.
21. Rizzo WB. Sjogren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency. Molecular genetics and metabolism. 2007; 90:1-9.
22. Puttmann L, Stehr H, Garshasbi M, Hu H, Kahrizi K, Lipkowitz B, Jamali P, Tzschach A, Najmabadi H, Ropers HH, Musante L, Kuss AW. A novel ALDH5A1 mutation is associated with succinic semialdehyde dehydrogenase deficiency and severe intellectual disability in an Iranian family. American journal of medical genetics Part A. 2013; 161a:1915-1922.
23. Muzio G, Maggiora M, Paiuzzi E, Oraldi M, Canuto RA. Aldehyde dehydrogenases and cell proliferation. Free radical biology & medicine. 2012; 52:735-746.
24. Bicknell LS, Pitt J, Aftimos S, Ramadas R, Maw MA, Robertson SP. A missense mutation in ALDH18A1, encoding Delta1-pyrroline-5-carboxylate synthase (P5CS), causes an autosomal recessive neurocutaneous syndrome. European journal of human genetics: EJHG. 2008; 16:1176-1186.
25. Ho KK, Mukhopadhyay A, Li YF, Mukhopadhyay S, Weiner H. A point mutation produced a class 3 aldehyde dehydrogenase with increased protective ability against the killing effect of cyclophosphamide. Biochemical pharmacology. 2008; 76:690-696.
26. Moreb JS, Ucar D, Han S, Amory JK, Goldstein AS, Ostmark B, Chang LJ. The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chemico-biological interactions. 2012; 195:52-60.
27. Januchowski R, Wojtowicz K, Zabel M. The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2013; 67:669-680.
28. Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, Honorio S, Xie Y, Scaglioni PP, DiMaio JM, Gazdar AF, Shay JW, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer research. 2010; 70:9937-9948.
29. Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, Wang J, Gonzalez R, Thompson DC, Norris DA, Roop DR, Vasiliou V, Fujita M. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem cells (Dayton, Ohio). 2012; 30:2100-2113.
30. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, Xerri L, Dontu G, Stassi G, Xiao Y, Barsky SH, Birnbaum D, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16:45-55.
31. Choi I, Lee S, Kyoung Chung H, Suk Lee Y, Eui Kim K, Choi D, Park EK, Yang D, Ecoiffier T, Monahan J, Chen W, Aguilar B, Lee HN, Yoo J, Koh CJ, Chen L, et al. 9-cis retinoic acid promotes lymphangiogenesis and enhances lymphatic vessel regeneration: therapeutic implications of 9-cis retinoic acid for secondary lymphedema. Circulation. 2012; 125:872-882.
32. Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood reviews. 2010; 24:S5-11.
33. Reghunathan R, Bi C, Liu SC, Loong KT, Chung TH, Huang G, Chng WJ. Clonogenic multiple myeloma cells have shared stemness signature assocuated with patient survival. Oncotarget. 2013; 4:1230-1240.
34. Hayward DG, Fry AM. Nek2 kinase in chromosome instability and cancer. Cancer letters. 2006; 237:155-166.
35. Chanan-Khan A. Bcl-2 antisense therapy in B-cell malignancies. Blood reviews. 2005; 19:213-221.
36. Blagosklonny MV. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell cycle (Georgetown, Tex). 2007; 6:70-74.
37. Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, Hardcastle T, Lee A, Roy R, East P, Kschischo M, Endesfelder D, Wylie P, Kim SN, Chen JG, Howell M, et al. Chromosomal instability determines taxane response. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:8671-8676.
38. Allahverdiyev AM, Bagirova M, Oztel ON, Yaman S, Abamor ES, Koc RC, Ates SC, Elcicek S, Baydar SY. Aldehyde Dehydrogenase: Cancer and Stem Cells 2012.
39. Yang Y, Shi J, Tolomelli G, Xu H, Xia J, Wang H, Zhou W, Zhou Y, Das S, Gu Z. RARa2 expression confers myeloma stem cell features. Blood. 2013; 122:1437-1447.
40. Sartore RC, Campos PB, Trujillo CA, Ramalho BL, Negraes PD, Paulsen BS, Meletti T, Costa ES, Chicaybam L, Bonamino MH, Ulrich H and Rehen SK. Retinoic acid-treated pluripotent stem cells undergoing neurogenesis present increased aneuploidy and micronuclei formation. PloS one. 2011; 6:e20667.
41. Wang S, Tricot G, Shi L, Xiong W, Zeng Z, Xu H, Zangari M, Barlogie B, Shaughnessy JD, Jr. Zhan F. RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood. 2009; 114:600-607.
42. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, et al. The molecular classification of multiple myeloma. Blood. 2006; 108:2020-2028.
43. Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, Wu Y, Xiao F, Liu Y, Yang Y. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget. 2010; 1:22.
44. Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, Barlogie B, Shaughnessy JD, Jr. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2-and p27Kip1-dependent and-independent mechanisms. Blood. 2007; 109:4995-5001.